Flow Cytometry Minimal Residual Disease Evolution Pattern Matters for Patients with Multiple Myeloma

Multiple myeloma (MM) is a malignant tumor of plasma cells that infiltrate the bone marrow and secrete monoclonal immunoglobulins, resulting in hypercalcemia, impaired renal function, anemia, bone lesions, and other related complications [1]. With the wide application of autologous stem cell transplant (ASCT) and novel agents including proteasome inhibitors and immunomodulators, both response depth and long-term survival have been significantly improved in MM patients [2]. Minimal residual disease (MRD) but not traditional complete response (CR) may provide the need for a deeper evaluation of the efficacy in patients with MM.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research